All In Biotech

Drug Trial Radar · NCT05767346

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

175

Actual

Start

Jun 20, 2023

Primary completion

Feb 28, 2025

Study completion Mar 28, 2025

Sponsor

Lead sponsor
CytokineticsIndustry
Sponsor type
Industry
Collaborators
Sanofi
First posted
Mar 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction

Conditions

  • Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions

  • Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)Drug

    Aficamten (CK-3773274) tablets administered orally

  • Placebo to match aficamtenDrug

    Placebo for aficamten (CK-3773274) administered orally

  • Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)Drug

    Metoprolol succinate tablets administered orally

  • Placebo to match metoprolol succinateDrug

    Placebo for metoprolol succinate administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET)Time frame: Baseline to Week 24

Locations

71 sites in 13 countries. Site status is shown where the registry gives one.

  • Alaska Heart and Vascular Institute

    Anchorage, Alaska

  • Mayo Clinic

    Phoenix, Arizona

  • UC San Diego Health - Sulpizio Cardiovascular Center

    La Jolla, California

  • Cedars-Sinai Medical Center (Smidt Heart Institute)

    Los Angeles, California

  • Yale New Haven Hospital

    New Haven, Connecticut

  • AdventHealth

    Orlando, Florida

  • Emory Clinic

    Atlanta, Georgia

  • Piedmont Fayette Hospital

    Fayetteville, Georgia

  • Northwestern University

    Evanston, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Lahey Hospital & Medical Center

    Burlington, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Saint Luke's Hospital of Kansas City

    Kansas City, Missouri

  • Morristown Medical Center

    Morristown, New Jersey

  • Columbia University Medical Center/New York Presbyterian Hospital

    New York, New York

  • Sanger Heart & Vascular Institute - HCM Clinic

    Charlotte, North Carolina

  • Duke Health Center Arringdon

    Morrisville, North Carolina

  • Providence St. Vincent Medical Center

    Portland, Oregon

  • Oregon Health & Science University

    Portland, Oregon

  • Division of Heart Failure and Transplantation (Hospital of the University of Pennsylvania)

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Ascension Saint Thomas Heart West

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • CHI St. Luke's Health Baylor-St. Luke's Medical Center

    Houston, Texas

  • Houston Methodist Hospital

    Houston, Texas

  • Intermountain Medical Center

    Murray, Utah

  • Inova Schar Heart and Vascular

    Falls Church, Virginia

  • Institutdo Danta Pazzanese

    Ibirapuera, Brazil

  • Instituto de Pesquisa Clinica de Campinas - IPECC

    Campinas, São Paulo, Brazil

  • lnstituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo

    São Paulo, São Paulo, Brazil

  • Institut universitaire de cardiologie et de pneumonlogie de Quebec - Universite Laval

    Québec, Canada

  • Xiangya Second Hospital of Central South University

    Changsha, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, China

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • Zhongshan Hospital Fudan University

    Shanghai, China

  • Renmin Hospital of Wuhan University

    Wuhan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

  • Aarhus University Hospital

    Aarhus, Denmark

  • Copenhagen University Hospital

    Copenhagen, Denmark

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.